Q3 EPS Estimate for Kymera Therapeutics Raised by Analyst

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) - Equities research analysts at Brookline Capital Management raised their Q3 2025 earnings per share (EPS) estimates for Kymera Therapeutics in a research report issued to clients and investors on Monday, July 7th. Brookline Capital Management analyst L. Cann now forecasts that the company will earn ($0.92) per share for the quarter, up from their prior estimate of ($1.03). The consensus estimate for Kymera Therapeutics' current full-year earnings is ($2.79) per share. Brookline Capital Management also issued estimates for Kymera Therapeutics' Q4 2025 earnings at ($0.95) EPS, FY2025 earnings at ($3.03) EPS, FY2026 earnings at ($4.29) EPS, FY2027 earnings at ($4.74) EPS, FY2028 earnings at ($5.68) EPS and FY2029 earnings at ($5.11) EPS.

A number of other research analysts have also commented on the company. B. Riley raised Kymera Therapeutics from a "neutral" rating to a "buy" rating and upped their price target for the company from $38.00 to $60.00 in a research report on Tuesday, June 3rd. Stifel Nicolaus assumed coverage on Kymera Therapeutics in a report on Tuesday, May 20th. They set a "buy" rating and a $55.00 target price for the company. Oppenheimer reaffirmed an "outperform" rating and issued a $53.00 price target (down previously from $56.00) on shares of Kymera Therapeutics in a research note on Friday, June 27th. HC Wainwright reissued a "buy" rating and set a $60.00 price objective (up from $54.00) on shares of Kymera Therapeutics in a research report on Thursday, June 26th. Finally, Wall Street Zen upgraded shares of Kymera Therapeutics from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. Two research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Kymera Therapeutics has an average rating of "Moderate Buy" and an average target price of $59.11.

Kymera Therapeutics Trading Down 0.9%

Shares of NASDAQ:KYMR opened at $43.43 on Wednesday. The company has a 50-day moving average price of $38.86 and a 200-day moving average price of $35.95. The company has a market cap of $2.83 billion, a price-to-earnings ratio of -14.01 and a beta of 2.18. Kymera Therapeutics has a 12 month low of $19.45 and a 12 month high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last posted its quarterly earnings results on Friday, May 9th. The company reported ($0.82) EPS for the quarter, beating analysts' consensus estimates of ($0.92) by $0.10. The company had revenue of $22.10 million during the quarter, compared to analyst estimates of $11.38 million. Kymera Therapeutics had a negative net margin of 409.07% and a negative return on equity of 30.11%. The firm's revenue was up 114.6% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.69) EPS.

Insider Buying and Selling

In other Kymera Therapeutics news, Director Elena Ridloff sold 12,000 shares of the stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $46.10, for a total transaction of $553,200.00. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Nello Mainolfi sold 30,000 shares of the business's stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $49.00, for a total value of $1,470,000.00. Following the completion of the transaction, the chief executive officer owned 660,482 shares of the company's stock, valued at $32,363,618. This represents a 4.34% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 48,349 shares of company stock worth $2,334,301 over the last quarter. 16.01% of the stock is owned by insiders.

Institutional Trading of Kymera Therapeutics

A number of institutional investors have recently made changes to their positions in KYMR. Northern Trust Corp lifted its position in Kymera Therapeutics by 14.0% during the fourth quarter. Northern Trust Corp now owns 437,833 shares of the company's stock valued at $17,614,000 after purchasing an additional 53,658 shares during the period. Ameriprise Financial Inc. bought a new position in Kymera Therapeutics in the fourth quarter valued at about $344,000. GAMMA Investing LLC boosted its position in Kymera Therapeutics by 3,851.5% in the first quarter. GAMMA Investing LLC now owns 6,678 shares of the company's stock worth $183,000 after purchasing an additional 6,509 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Kymera Therapeutics by 5.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 387,187 shares of the company's stock valued at $15,577,000 after purchasing an additional 20,346 shares during the period. Finally, Millennium Management LLC grew its stake in shares of Kymera Therapeutics by 205.0% during the 4th quarter. Millennium Management LLC now owns 115,918 shares of the company's stock valued at $4,663,000 after purchasing an additional 77,912 shares during the period.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.